Open Access
CC BY 4.0 · Chinese medicine and natural products 2024; 04(01): e8-e17
DOI: 10.1055/s-0044-1782181
Review Article

Effect of Microneedle on Hair Regrowth in Patients with Androgenetic Alopecia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Chunyan Xu
1   Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing China
,
Xingwu Duan
1   Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing China
,
Qiang Yin
1   Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing China
,
Keshuai Liu
1   Department of Dermatology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing China
› Institutsangaben

Funding This work was supported by the National Natural Science Foundation (8207151023).
Preview

Abstract

Objective Our objective was to assess the effectiveness and safety of microneedle by comparing microneedle plus 5% topical minoxidil treatment and microneedle alone to 5% topical minoxidil.

Methods We searched databases such as Embase, PubMed, Cochrane library, VIP Database for Chinese Technical Periodicals, Wanfang, and China National Knowledge Infrastructure in relation to literature. The control group received 5% topical minoxidil solution, whereas the treatment group received either microneedle coupled with minoxidil or microneedle alone. The increase in hair count and hair diameter was the main evaluation criterion for assessing hair regrowth. Data were pooled with Stata 15 software.

Results Eight studies with 472 participants were included. Compared with 5% topical minoxidil therapy, microneedle plus minoxidil treatment showed a significant increase in hair count (standard mean difference [SMD] :15.82, 95% confidence interval [CI]: 12.34, 19.31, p < 0.05), but no increase in hair diameter (SMD: −0.21, 95% CI: −2.94, 2.52, p = 0.879 > 0.05). The results of subgroup analysis suggested that microneedle plus minoxidil treatment showed a significant increase in hair count whether the depth of microneedle was less than 1 mm (SMD:1.16, 95% CI: 0.86, 1.42, p < 0.05) or more than 1 mm (SMD:0.52, 95% CI: 0.23, 0.82, p < 0.05). In terms of treatment period subgroup, microneedle combined with minoxidil therapy significantly increased hair count and hair diameter than single 5% topical minoxidil, whether in 12-week period (SMD: 1.08, 95% CI: 0.76, 1.39, p < 0.05) or 21 to 24 weeks period (SMD: 0.64: 95%, CI: 0.35, 0.92, p < 0.05).

Conclusion According to this study, the effect of microneedle treatment alone on androgenetic alopecia (AGA) may be limited. However, microneedle plus 5% topical minoxidil treatment had better hair regrowth in hair count and can be considered as an additional therapy option for AGA. Combined with subgroup analysis results, 12-week period and less than 1 mm depth of microneedle penetration were recommended.

CRediT Authorship Contribution Statement

Chunyan Xu: Conceptualization, project administration, data curation, formal analysis, writing-original draft, and writing-review and editing. Xingwu Duan: Project administration, supervision, and writing-review and editing. Qiang Yin: Data curation, formal analysis, and writing-review and editing. Keshuai Liu: Data curation, formal analysis, and writing-review and editing.


Supplementary Material



Publikationsverlauf

Eingereicht: 02. November 2023

Angenommen: 22. Dezember 2023

Artikel online veröffentlicht:
30. März 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Hochfeld LM, Keller A, Anhalt T, Fricker N, Nöthen MM, Heilmann-Heimbach S. Meta-analysis for Androgenetic Alopecia Novel determinants (MAAN) Consortium. Insights into male androgenetic alopecia: differential gene expression profiling of plucked hair follicles and integration with genetic data. J Invest Dermatol 2019; 139 (01) 235-238
  • 2 Wang TL, Zhou C, Shen YW. et al. Prevalence of androgenetic alopecia in China: a community-based study in six cities. Br J Dermatol 2010; 162 (04) 843-847
  • 3 Aukerman EL, Jafferany M. The psychological consequences of androgenetic alopecia: a systematic review. J Cosmet Dermatol 2023; 22 (01) 89-95
  • 4 Kelly Y, Blanco A, Tosti A. Androgenetic alopecia: an update of treatment options. Drugs 2016; 76 (14) 1349-1364
  • 5 Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol 2021; 20 (12) 3759-3781
  • 6 Yu CQ, Zhang H, Guo ME. et al. Combination therapy with topical minoxidil and nano-microneedle-assisted fibroblast growth factor for male androgenetic alopecia: a randomized controlled trial in Chinese patients. Chin Med J (Engl) 2020; 134 (07) 851-853
  • 7 Faghihi G, Nabavinejad S, Mokhtari F, Fatemi Naeini F, Iraji F. Microneedling in androgenetic alopecia; comparing two different depths of microneedles. J Cosmet Dermatol 2021; 20 (04) 1241-1247
  • 8 Yu AJ, Luo YJ, Xu XG. et al. A pilot split-scalp study of combined fractional radiofrequency microneedling and 5% topical minoxidil in treating male pattern hair loss. Clin Exp Dermatol 2018; 43 (07) 775-781
  • 9 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (07) e1000097
  • 10 Higgins JP, Altman DG, Gøtzsche PC. et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
  • 11 Liang XL, Liu Y, Wu HX. Efficacy and safety of topical minoxidil solution alone and combined with microneedle and Yu fa via microneedle on the treatment of non-menopausal female pattern hair loss. Journal of Clinical and Experimental Medicine 2022; 7 (21) 739-744
  • 12 Bao L, Gong L, Guo M. et al. Randomized trial of electrodynamic microneedle combined with 5% minoxidil topical solution for the treatment of Chinese male androgenetic alopecia. J Cosmet Laser Ther 2020; 22 (01) 1-7
  • 13 Kumar MK, Inamadar AC, Palit A. A randomized controlled, single-observer blinded study to determine the efficacy of topical minoxidil plus microneedling versus topical minoxidil alone in the treatment of androgenetic alopecia. J Cutan Aesthet Surg 2018; 11 (04) 211-216
  • 14 Bao L, Zong H, Fang S, Zheng L, Li Y. Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway. J Dermatolog Treat 2022; 33 (01) 483-493
  • 15 Sang ZW, Feng HX, Zhao BJ. Clinical effects of microneedling at different depths combined with external minoxidil tincture on male androgenetic alopecia. J Diagn Ther Dermato-Venereol 2022; 4 (29) 322-326
  • 16 Katzer T, Leite Junior A, Beck R, da Silva C. Physiopathology and current treatments of androgenetic alopecia: going beyond androgens and anti-androgens. Dermatol Ther 2019; 32 (05) e13059
  • 17 Lee CS, Kang JA, Kim GY. et al. A study on the effect of Eclipta prostrata extract and MTS on the improvement of scalp health and prevention of hair loss for workers in their 20s and 30s. Med-Leg Update 2020; 20: 1850-1856
  • 18 Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatolog Treat 2022; 33 (04) 1896-1906
  • 19 Yang D, Chen M, Sun Y. et al. Microneedle-mediated transdermal drug delivery for treating diverse skin diseases. Acta Biomater 2021; 121: 119-133
  • 20 Chun HS, Song HS. Analysis of trend of studies on microneedle treatment system (MTS). J Pharmacopuncture 2021; 24 (04) 182-190
  • 21 Ziaeifar E, Ziaeifar F, Mozafarpoor S, Goodarzi A. Applications of microneedling for various dermatologic indications with a special focus on pigmentary disorders: a comprehensive review study. Dermatol Ther 2021; 34 (06) e15159
  • 22 Sohng C, Lee EH, Woo SK. et al. Usefulness of home-use microneedle devices in the treatment of pattern hair loss. J Cosmet Dermatol 2021; 20 (02) 591-596
  • 23 Fertig RM, Gamret AC, Cervantes J, Tosti A. Microneedling for the treatment of hair loss?. J Eur Acad Dermatol Venereol 2018; 32 (04) 564-569
  • 24 Gu Y, Bian Q, Zhou Y, Huang Q, Gao J. Hair follicle-targeting drug delivery strategies for the management of hair follicle-associated disorders. Asian J Pharm Sci 2022; 17 (03) 333-352
  • 25 Vora LK, Donnelly RF, Larrañeta E, González-Vázquez P, Thakur RRS, Vavia PR. Novel bilayer dissolving microneedle arrays with concentrated PLGA nano-microparticles for targeted intradermal delivery: proof of concept. J Control Release 2017; 265: 93-101
  • 26 Yuan A, Gu Y, Bian Q. et al. Conditioned media-integrated microneedles for hair regeneration through perifollicular angiogenesis. J Control Release 2022; 350: 204-214
  • 27 Sharma A, Surve R, Dhurat R. et al. Microneedling improves minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. J Biol Regul Homeost Agents 2020; 34 (02) 659-661
  • 28 Jha AK, Vinay K. Androgenetic alopecia and microneedling: every needling is not microneedling. J Am Acad Dermatol 2019; 81 (02) e43-e44
  • 29 Vicente-Perez EM, Larrañeta E, McCrudden MTC. et al. Repeat application of microneedles does not alter skin appearance or barrier function and causes no measurable disturbance of serum biomarkers of infection, inflammation or immunity in mice in vivo. Eur J Pharm Biopharm 2017; 117: 400-407